NTLA — INTELLIA THERAPEUTICS INC

Ownership history in Discovery Value Fund  ·  20 quarters on record

This page tracks every 13F SEC filing in which Discovery Value Fund reported a position in INTELLIA THERAPEUTICS INC (NTLA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
11.62% (2023 Q2)
Avg. % of fund
5.92%
First filed
2021 Q1
Last filed
2025 Q4
Quarters held
20
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 97,976 -130,725 -57.2% 2.35% $881K $8.99
2025 Q3 UNCHANGED 228,701 — 0% 7.05% $3.9M $17.27
2025 Q2 REDUCED 228,701 -332,860 -59.3% 4.16% $2.1M $9.38
2025 Q1 UNCHANGED 561,561 — 0% 5.66% $4.0M $7.11
16 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    NTLA price (monthly, adj. close)

Other funds also holding NTLA

As of 2025 Q4 — sorted by position size

REGENERON PHARMACEUTICALS, INC. 98.49% Birchview Capital, LP 3Y 7Y 1.66% ARK Investment Management LLC 3Y 7Y 0.85% Orchard Capital Management, LLC 3Y 0.64% IQ EQ FUND MANAGEMENT (IRELAND) Ltd 3Y 7Y 0.45% HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 3Y 0.32% Amova Asset Management Americas, Inc. 3Y 7Y 0.23% Elmwood Wealth Management, Inc. 3Y 7Y 0.22% Headlands Technologies LLC 3Y 0.18% GSA CAPITAL PARTNERS LLP 3Y 7Y 0.18%
← Back to Discovery Value Fund Holdings